Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Alabama at Birmingham
About this trial
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.
We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Healthy adult
Disqualifiers
No prior history of pneumococcal vaccination
No immunosuppressing medications or chronic diseases that affect immune function
Trial design
Design model
Parallel
Treatments tested in this trial
Pneumococcal Vaccine
Biological/VaccinePCV
Treatment groups
70 Participants
are divided into 2 treatment groupsGroup A: PCV20Experimental treatment 1 intervention
Group B: PCV21Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Serogroup 33 antibodies
Serum antipneumococcal antibody concentrations (micrograms/mL) against members of serogroup 33, measured using WHO-ELISA
Time frame
4 weeks post-vaccination2
Antibody-mediated killing
Opsonic activity of vaccine-induced antibodies (reported as opsonic index, or OI); measured using an opsonophagocytic killing (OPK) assay.
Time frame
4 weeks post-vaccinationSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Alabama at Birmingham
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov